The main purpose of this study is to assess how well the study drug (JNJ-42847922) works (efficacy) compared with placebo in improving depressive symptoms in participants with major depressive disorder (\[MDD\], a common mood disorder that causes a lasting feeling of sadness and a loss of interest in everyday activities) in double-blind treatment phase. Further, to evaluate long-term safety and tolerability of JNJ-42847922 in participants with MDD in the open label treatment phase.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Double Blind (DB) Treatment Phase: Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score in Participants with Major Depressive Disorder with Moderate-to-Severe Insomnia Symptoms (MDDIS)
Timeframe: Baseline up to Day 43
Open-Label (OL) Treatment Phase: Number of Participants with Adverse Events Including Adverse Event of Special Interests (AESIs)
Timeframe: OL Baseline (Day 43) Up to 6 months
OL Treatment Phase: Number of Participants with Vital Signs Abnormalities
Timeframe: OL Baseline (Day 43) Up to 6 months
OL Treatment Phase: Number of Participants with Suicidality Assessment using Columbia-Suicide Severity Rating Scale (C-SSRS)
Timeframe: OL Baseline (Day 43) Up to 6 months
OL Treatment Phase: Number of Participants with Withdrawal Symptoms Assessment Using Physician Withdrawal Checklist (PWC-20)
Timeframe: End of Treatment/Early withdrawal to end of the Follow-up visit (up to 14 days)
OL Treatment Phase: Number of Participants with Abnormalities in Electrocardiogram (ECG)
Timeframe: OL Baseline (Day 43) up to 6 months
OL Treatment Phase: Number of Participants Reporting Sexual Functioning using Arizona Sexual Experiences Scale (ASEX)
Timeframe: Up to 6 months
OL Treatment Phase: Change from Baseline in the Body Weight
Timeframe: OL Baseline (Day 43) up to 6 months
OL Treatment Phase: Change from Baseline in the Body Mass Index (BMI)
Timeframe: OL Baseline (Day 43) up to 6 months
OL Treatment Phase: Change from Baseline in the Waist Circumference
Timeframe: OL Baseline (Day 43) up to 6 months
OL Treatment Phase: Number of Participants with Abnormalities in Clinical Laboratory Parameters
Timeframe: OL Baseline (Day 43) up to 6 months